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Gender differences in renal responses to hyperglycemia and
angiotensin-converting enzyme inhibition in diabetes.
Background. Diabetes mellitus reduces female gender-
mediated protection against progression of renal disease but the
mechanisms responsible for this loss of protection are unknown.
The impact of gender on the diabetic hyperfiltration state has
not previously been studied. Since hyperfiltration is a factor in
the development of diabetic renal disease, and is influenced by
hyperglycemia and renin-angiotensin system (RAS) blockade,
we examined gender differences in the renal response to hyper-
glycemia and angiotensin-converting enzyme (ACE) inhibition
in young males and females with uncomplicated type 1 diabetes
mellitus.
Methods. Ten male and 12 female normoalbuminuric, nor-
motensive, adolescents with type 1 diabetes mellitus were stud-
ied before ACE inhibition during clamped euglycemia and
hyperglycemia, and then after 21 days treatment with enalapril
(0.1 mg/kg daily × 1 week and then 0.1 mg/kg twice a day × 2
weeks).
Results. During clamped euglycemia, males exhibited sig-
nificantly higher effective renal plasma flow (ERPF) and
renal blood flow (RBF) and a lower renal vascular resis-
tance (RVR). During clamped hyperglycemia, females exhib-
ited reductions in ERPF and RBF, and increased RVR and
filtration fraction (FF). Males exhibited no significant renal
hemodynamic changes during hyperglycemia. After ACE in-
hibition treatment, both genders exhibited significant declines
in arterial pressure, but only females displayed a reduction in
glomerular filtration rate (GFR) and FF.
Conclusion. The renal responses to hyperglycemia and ACE
inhibition appear to differ between male and female adolescents
with uncomplicated type 1 diabetes mellitus. Hyperglycemia-
induced changes in RVR and FF in women may account, at
least in part, for the loss of gender-based protection in diabetic
renal disease.
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Diabetes mellitus is associated with a high risk for the
development of progressive renal disease [1–8]. Although
in nondiabetic renal disease, female gender is protec-
tive against the development of end-stage renal disease
(ESRD), in diabetes mellitus this protection is diminished
[1–6]. The mechanisms responsible for this loss of pro-
tection have not been fully elucidated. Increased renal
plasma flow and glomerular hyperfiltration are known
risk factors for the development of diabetic nephropa-
thy [7–9]. Poor glycemic control is also a risk factor for
the development and progression of diabetic nephropa-
thy, partly through hyperglycemia-mediated activation of
the renin-angiotensin system (RAS) [10]. Furthermore,
recent studies have identified important interactions be-
tween gender and the RAS [11], but the renal hemody-
namic response to hyperglycemia and blockade of the
RAS has not been compared in men and women with type
1 diabetes mellitus. Accordingly, the goal of the current
study was to test the hypothesis that gender differences in
the renal hemodynamic response to hyperglycemia and
RAS blockade might account for the loss of protection of
female gender in the development of diabetic nephropa-
thy. We studied subjects without clinical evidence of di-
abetic nephropathy in order to remove any confounding
effect of proteinuria or renal functional impairment.
Work from several laboratories suggests that abnor-
mal glomerular hemodynamic function may contribute
significantly to initiation or progression of renal disease
[7–9]. Specifically, glomerular hyperfiltration and renal
hyperperfusion [7–8] and an augmented hyperfiltration
response to hyperglycemia [12] are seen in diabetes
mellitus and are associated with deleterious high intra-
glomerular pressures, and may be important in the early
pathophysiology of diabetic nephropathy [13–15]. There-
fore, in the first experiment, we compared renal hemo-
dynamic function in adolescents with type 1 diabetes
mellitus during short-term clamped euglycemia (capillary
blood glucose 4 to 6 mmol/L) and short-term clamped
hyperglycemia (blood glucose 9 to 11 mmol/L). We then
studied renal hemodynamic function after a three-week
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course of RAS blockade during euglycemic conditions,
hypothesizing that any sex differences in the responses
to these maneuvers could further our understanding of
the impact of gender on the mechanisms that may under-
lie the predilection for developing diabetic renal disease.
METHODS
Subjects
The protocol was approved by the Research Ethics
Board of the Hospital for Sick Children, Toronto,
Canada. All patients and/or their parents gave informed
consent. Twenty-two adolescents (10 males and 12
females) with type 1 diabetes mellitus were recruited
from an ongoing longitudinal cohort study of ambula-
tory blood pressure monitoring at the Hospital for Sick
Children. Participants who fulfilled the following inclu-
sion criteria were asked to participate: duration of type
1 diabetes mellitus longer than 5 years, Tanner stage 2
to 5 puberty, normoalbuminuria [albumin excretion rate
(AER) < 20 lg/min on two of three overnight urine col-
lections obtained during the month prior to study], nor-
mal clinic blood pressure, and absence of chronic illness
other than treated hypothyroidism or mild asthma.
Protocol and evaluations
During the 7-day prestudy phase of each experi-
ment, subjects adhered to a sodium-replete (150 to 200
mmol/day) and protein-replete (1 to 1.5 g/kg/day) diet.
Compliance was determined by measuring the urinary
sodium and urea in overnight urine collections on days
5 and 6. Protein intake was calculated from the urea ex-
cretion using standard equations. Subjects were studied
if the excretion of sodium and urea were 2 to 3 mmol/kg
and 3 to 6 mmol/kg, respectively, in 24 hours. All subjects
met these study criteria.
Euglycemic or hyperglycemic conditions were main-
tained for 10 to 12 hours preceding and during the inves-
tigations. Female subjects were studied during the early
follicular phase of the menstrual cycle, determined by
counting days of the menstrual cycle and measuring 17b-
estradiol levels. None of the female subjects were taking
oral contraceptive medications.
Studies were carried out on 3 separate days. Subjects
were studied on day 1 during clamped euglycemia (blood
glucose = 4 to 6 mmol/L) and on day 2 during clamped
hyperglycemia (blood glucose = 9 to 11 mmol/L). After
21 days of enalapril (0.1 mg/kg daily ×1 week and then
0.1 mg/kg twice a day ×2 weeks), subjects were studied
on day 3 using the same procedure during euglycemic
conditions.
Subjects were admitted to the Clinical Investigation
Unit at the Hospital for Sick Children the evening before
each phase of the study. A 16-gauge peripheral venous
cannula was inserted into a vein in one arm for infusion
of glucose and insulin and a second blood sampling line
was inserted into a vein in the contralateral arm. Blood
glucose was measured every hour and the insulin infusion
was adjusted to maintain euglycemia (4 to 6 mmol/L).
Studies were conducted the following morning after an
overnight fast with subjects lying in the supine position
in a warm quiet room. A third intravenous line was in-
serted into the arm contralateral to the insulin infusion
and was connected to a syringe infusion pump for in-
fusions of inulin and paraminohippurate (PAH). Mean
arterial pressure (MAP) and heart rate were measured
prior to each blood sample throughout the study by an
automated sphygmomanometer (Dinamapp). After col-
lecting blood for inulin and PAH blank, a priming in-
fusion containing 25% inulin (60 mg/kg) and 20% PAH
(8 mg/kg) was administered. Thereafter, inulin and PAH
were infused continuously at a rate calculated to maintain
their respective plasma concentrations constant at 20 and
1.5 mg/dL. Subjects remained supine at all times. After a
90-minute equilibration period, blood was collected for
inulin, PAH, and hematocrit. Blood was further collected
each 20 minutes for 60 minutes, and glomerular filtration
rate (GFR) and effective renal plasma flow (ERPF) were
estimated by steady state infusion of inulin and PAH ac-
cording to the calculation method described by Schnurr
et al [16].
Sample collection and analytical methods
Blood samples collected for inulin and PAH determi-
nations were immediately centrifuged at 3000 rpm for
10 minutes at 4◦C. Plasma was separated, placed on ice,
and then stored at −70◦C before the assay. Inulin and
PAH were measured in serum by colorimetric assays
using anthrone and N-(1-naphthy) ethylenediamine, re-
spectively. The mean of the final two baseline clearance
periods represent GFR and ERPF, expressed per 1.73 m2.
Filtration fraction (FF) was determined as the ratio of
GFR to ERPF. Renal blood flow (RBF) was calculated
by dividing the ERPF by 1 hematocrit. Renal vascular
resistance (RVR) was derived by dividing MAP by the
RBF. Renal hemodynamic measurements were adjusted
for body surface area (BSA).
Urinary AER was determined from three timed
overnight urine collections. Urinary albumin concen-
tration was determined by immunoturbidimetry [17].
Hemoglobin A1c (HbA1c) was measured by high-
performance liquid chromatography (HPLC). The non-
diabetic range for our laboratory is 4% to 6.3% [18].
Statistical analysis
The data were analyzed on the basis of gender. Results
are presented as mean ± SEM. GFR, ERPF, and RBF
were corrected for BSA. Between-group comparisons of
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Table 1. Baseline characteristics (mean ± SEM)
Parameter Female Male P value
Age years 14.32 ± 1.64 15.40 ± 2.30 0.21
Body mass index kg/m2 24.59 ± 3.56 22.15 ± 1.88 0.07
Hemoglobin A1c% 8.56 ± 0.93 8.50 ± 1.2 0.89
Diabetes duration years 10.02 ± 2.61 11.54 ± 3.05 0.22
Protein intake g/kg/day 1.17 ± 0.04 1.21 ± 0.05 0.89
Urine Na+ mmol/day 144 ± 21 152 ± 18 0.23
Plasma renin activity ng angiotensin I/L/min 0.09 ± 0.002 0.08 ± 0.001 0.64
17b-estradiol pmol/L 62 ± 3 — —
Mean arterial blood pressure mm Hg 76.23 ± 5.65 78.30 ± 9.16 0.64
Table 2. Mean systemic and renal hemodynamic responses to hyperglycemia (mean ± SEM)
Female Male
Parameter Euglycemia Hyperglycemia P value Euglycemia Hyperglycemia P value
Mean arterial blood pressure mm Hg 76.87 ± 7.51 78.04 ± 10.09 0.52 78.38 ± 7.36 74.62 ± 8.82 0.41
Glomerular filtration rate mL/min/1.73 m2 135.59 ± 43.96 144.37 ± 21.44 0.07 155.20 ± 59.89 145.96 ± 25.28 0.39
Effective renal plasma flow mL/min/1.73 m2 647.61 ± 122.65 589.35 ± 77.98 0.001 796.67 ± 206.16 761.25 ± 119.77 0.43
Filtration fraction 0.21 ± 0.05 0.24 ± 0.04 0.01 0.20 ± 0.08 0.20 ± 0.03 0.73
Renal blood flow mL/min/1.73 m2 1039.93 ± 171.34 935.37 ± 99.14 0.004 1339.63 ± 373.09 1285.98 ± 194.52 0.45
Renal vascular resistance mm Hg/L/min 75.89 ± 12.15 84.49 ± 14.28 0.01 61.92 ± 13.58 59.39 ± 9.11 0.83
all parameters at baseline were made using parametric
methods (unpaired t test). Within-subject-and-between-
group differences in the response to hyperglycemia and
ACE inhibitors were determined by analysis of variance
(ANOVA). All statistical analyses were performed using
the statistical package SAS (SAS Institute Inc., Cary, NC,
USA).
RESULTS
Baseline parameters: Clamped euglycemia
and hyperglycemia
At baseline, the male and female groups were not sig-
nificantly different in terms of age, HbA1c, body mass
index (BMI), MAP, diabetes duration, urine sodium ex-
cretion, protein intake, or plasma renin activity (PRA).
In females, 17b-estradiol levels were consistent with the
early follicular phase (Table 1). During clamped eug-
lycemia (Table 2), males exhibited significantly higher
ERPF (P = 0.048) and RBF (P = 0.037), after cor-
rection for BSA. RVR was significantly lower in males
(P = 0.019). Although the GFR in males was numerically
higher than in females, the values did not differ signifi-
cantly. FF and MAP did not differ significantly between
the two groups.
During clamped hyperglycemia compared to clamped
euglycemia (Table 2), females exhibited a trend toward
an elevation in GFR (P = 0.07), a significant reduction in
ERPF, and RBF with a significant rise in RVR and FF. In
response to hyperglycemia, males did not display any sig-
nificant alterations in renal hemodynamic function. The
hyperglycemia-mediated renal hemodynamic changes in
GFR (P = 0.023), FF (P = 0.014), and RVR (P = 0.01)
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Fig. 1. Gender difference in glomerular filtration rate (GFR) re-
sponses to hyperglycemia and angiotensin-converting enzyme in-
hibitors (ACEI). The change () in GFR in response to hyperglycemia
and ACE inhibitors in females and males with uncomplicated type 1
diabetes mellitus. ∗P < 0.05 versus response in females.
were significantly different in males compared to females
(Figs. 1 to 3).
Response to ACE inhibitors
Males and females both exhibited significant reduc-
tions in MAP during clamped euglycemia post-ACE in-
hibition (Table 3). Females experienced a significant fall
in GFR and FF with no significant change in ERPF, RBF,
or RVR. In contrast, no significant change in any re-
nal hemodynamic parameter was observed in males. The
changes in GFR (P = 0.04), FF (P = 0.01), and RVR
(P = 0.01) responses to ACE inhibitors were significantly
different in males compared to females (Figs. 1 to 3).
DISCUSSION
The protective effect of female gender in nondiabetic
renal disease is diminished in diabetes mellitus [1–6], and
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Fig. 2. Gender difference in renal vascular resistance (RVR) re-
sponses to hyperglycemia and angiotensin-converting enzyme in-
hibitors (ACEI). The change () in RVR in response to hyperglycemia
and ACE inhibitors in females and males with uncomplicated type 1
diabetes mellitus. ∗P < 0.05 versus response in females.
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Fig. 3. Gender difference in filtration fraction (FF) responses to hyper-
glycemia and angiotensin-converting enzyme inhibitors (ACEI). The
change () in FF in response to hyperglycemia and ACE inhibitors in
females and males with uncomplicated type 1 diabetes mellitus. ∗P <
0.05 versus response in females.
the goal of the current study was to identify mechanisms
that might be responsible for the loss of female gender
protection. Our major findings were (1) although males
exhibited significantly higher ERPF and RBF and lower
RVR at baseline during euglycemia, the renal hemo-
dynamic response to hyperglycemia was augmented in
women compared to men; (2) RAS blockade decreased
GFR and FF in females but not in males during clamped
euglycemia.
To our knowledge there are no previous studies ex-
amining gender differences in the renal hemodynamic
profile that characterize the early, clinically silent phase
of type 1 diabetes mellitus. The finding that males ex-
hibited significantly higher baseline ERPF and RBF and
lower RVR during euglycemia than did females sug-
gests that renal hyperperfusion and hyperfiltration may
be more common at this stage of type 1 diabetes melli-
tus in young males. In animal models, female nondiabetic
rats have been shown to have higher afferent and efferent
arteriolar resistances (and higher RVR) and lower RBF
compared to male rats [19], which is consistent with the
findings from our study. Conceivably, increased RVR
might indicate increased afferent arteriolar tone, which in
turn could protect the kidneys from hyperfiltration and
hyperperfusion injury [20], delaying the progression to
overt nephropathy. Similar hemodynamic observations
were made in large-scale human studies in the 1940s and
1950s, which examined gender-based differences in renal
hemodynamic function in healthy nondiabetic humans,
and also found that women exhibit lower RBF [21–23],
which is again consistent with findings from our current
study. It is therefore tempting to speculate that the loss
of afferent arteriolar tone, which is considered character-
istic of the diabetic kidney [24], may be primarily a male
phenomenon.
Interestingly, although studies in nondiabetic female
animal and human models usually conclude that females
exhibit significantly lower arterial pressure levels than do
males [25], in our study, there were no significant gender
differences in MAP. It has been demonstrated that, after
the onset of puberty, boys exhibit higher blood pressure
than do age-matched girls, but at age 13 to 15 years (the
age range in which the majority of our subjects fell) the
difference is only approximately 4 mm Hg [26], but even
this difference was not evident in our study. We are not
aware of any large-scale studies that have examined blood
pressure differences in males and females with type 1 di-
abetes mellitus, but since some of the protective effect of
gender is purported to stem from lower arterial pressure
in females [27], it would be appropriate to examine in
larger samples whether the usual gender differences are
lost in this population.
During the clamped hyperglycemic phase of the study,
females experienced significant decreases in ERPF and
RBF, and an elevation in FF. The rise in FF suggests that
the acute alteration in renal hemodynamic function was
that of a greater increase in efferent relative to afferent
arteriolar resistance. Such an effect, perhaps secondary
to hyperglycemia-mediated RAS activation [10] would
be associated with an increase in intraglomerular hydro-
static pressure. Interestingly, men exhibited little change
in renal hemodynamic function in response to short-term
hyperglycemia. We have previously shown that the vaso-
constrictive response to RAS activation is blunted in fe-
males during the high estrogen phases of the menstrual
cycle [11]. The augmented renal hemodynamic response
to hyperglycemia in females in this study may have been
partially because the studies in females were carried out
during the follicular, low estrogen phase of the menstrual
cycle. Although the mechanisms responsible for the in-
creased renal hemodynamic response to hyperglycemia
in females compared to males were not determined in
this study, the predicted increase in glomerular capillary
pressure may account for the clinical observation that fe-
male gender is not protective in diabetic nephropathy,
glomerular capillary hypertension being a critical hemo-
dynamic determinant of diabetic kidney disease progres-
sion [28–31].
The finding that ACE inhibitors resulted in beneficial
reductions in GFR and FF only in females is consistent
with studies in animals with and without experimental
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Table 3. Mean systemic and renal hemodynamic responses to angiotensin-converting enzyme (ACE) inhibitors (mean ± SEM)
Female Male
Parameter Euglycemia Post-ACE inhibitor P value Euglycemia Post-ACE inhibitor P value
Mean arterial blood pressure mm Hg 76.87 ± 7.51 71.37 ± 6.35 0.0002 78.38 ± 7.36 70.13 ± 6.23 0.002
Glomerular filtration rate mL/min/1.73 m2 135.59 ± 43.96 112.65 ± 24.17 0.04 155.20 ± 59.89 151.16 ± 44.10 0.64
Effective renal plasma flow mL/min/1.73 m2 647.61 ± 122.65 639.15 ± 134.46 0.55 796.67 ± 206.16 777.72 ± 150.60 0.58
Filtration fraction 0.21 ± 0.05 0.18 ± 0.04 0.05 0.20 ± 0.08 0.20 ± 0.07 0.71
Renal blood flow mL/min/1.73 m2 1039.93 ± 171.34 1013.04 ± 188.43 0.34 1339.63 ± 373.09 1297.12 ± 257.20 0.58
Renal vascular resistance mmHg/L/min 75.89 ± 12.15 74.74 ± 15.69 0.69 61.92 ± 13.58 55.79 ± 12.36 0.19
diabetes and humans with and without diabetes mellitus
that examined the interaction between the RAS and es-
trogen [20, 32–37]. Animal models have demonstrated
a reduction in serum ACE levels, tissue ACE activity
and renal medullary ACE mRNA in response to estrogen
[32]. The same study demonstrated an estrogen-mediated
decrease in blood pressure, which was attributed to the
observed reduction in RAS activity [32]. Studies in rat
models have demonstrated that estrogen attenuates the
responses to infusions of angiotensin II (Ang II) [33],
and that 17b-estradiol replacement in ovariectomized
diabetic rats reduces functional renal impairment,
pathologic indices of glomerulosclerosis and interstitial
fibrosis, urinary AER and transforming factor-b pro-
tein expression [38]. Gender-based differences in RAS
function have also been shown in nondiabetic humans,
including a blunted ERPF and FF response to Ang II
infusion in women compared to men, especially in high
estrogen states of the menstrual cycle [34]. In addition,
alterations in components of the RAS and responsive-
ness of the RAS at the level of the peripheral vascula-
ture [20] and renal vasculature [35] have been previously
demonstrated. In humans with type 2 diabetes mellitus,
hormone replacement therapy has been associated with a
reduction in proteinuria and an increase in renal function
[37]. Data from the Ramipril Efficacy in Nephropathy
(REIN) study in nondiabetic renal disease showed that
women experienced a significantly increased antiprotein-
uric effect from ACE inhibitors compared to men [36].
Women maintained on ramipril also exhibited a smaller
decline in GFR over time, and a lower incidence of ESRD.
This female gender-mediated augmented renal response
to ACE inhibitors may be due to a synergistic effect of
ACE inhibitors and estrogen on components of the RAS.
Animal models examining the physiologic interaction be-
tween RAS blockade and estrogen have demonstrated
synergistic effects leading to a reduction in deleterious
vascular remodeling [39]. It is tempting to speculate that
this phenomenon is also relevant to the hemodynamic ef-
fects of RAS activation. In the case of the present study,
even though the experiments were carried out during the
follicular phase, we noted an augmented response to ACE
inhibitors in females, suggesting that any level of estrogen
may act synergistically with RAS blockade.
The influence of gender on progression of diabetic
nephropathy has been examined in at least six outcome
studies by different investigators [1–6]. The studies by
Mangili et al [1], Orchard et al [2], and Jacobsen et al
[3] found associations between male gender and worse
outcomes as measured by albuminuria in the first two
studies and the change in GFR in the third. The study by
Orchard et al [2] reported a higher risk of nephropathy
in women with a short duration of diabetes, and a lower
risk with longer duration. Three other studies in a total of
1301 patients found no impact of gender on progression
of diabetic renal disease [4–6]. From these studies it is ap-
parent that women with diabetes mellitus as the cause of
their chronic kidney disease do not have the same de-
gree of protection against progression as women with
nondiabetic renal disease [1–6, 40]. The present study
has demonstrated that although females appeared to ex-
hibit a protective renal hemodynamic response to ACE
inhibitors, their response to hyperglycemia was deleteri-
ous, resulting in a physiologic profile that could favor the
development and progression of disease.
This study has some important limitations. The sam-
ple size was small which probably contributed to the fail-
ure to reach statistical significance in some measurements
(for example the GFR response to hyperglycemia in fe-
males). We attempted to correct for this by construct-
ing homogenous groups and by careful prestudy prepa-
ration. In addition we used a paired design that allowed
each subject to act as his/her own control, thereby de-
creasing variability and allowing us to reach some sig-
nificant conclusions. Responses to RAS blockade can be
influenced by prestudy differences in effective circulat-
ing volume [41]. We avoided this confounding effect by
ensuring that our subjects were sodium replete, and by
monitoring compliance with 24-hour urine collections for
sodium excretion. Further, extreme hyperglycemia can
activate the RAS through volume contraction induced
by glucosuria. We protected against this by clamping
blood glucose at 9 to 11 mmol/L in the hyperglycemic
phase, below the threshold for glucosuria. Women ex-
hibit variations in renal hemodynamic and RAS function
throughout the menstrual cycle [11] or while taking oral
contraceptive medications [42]. We reduced the impact
of these factors by studying only female subjects who
Cherney et al: Gender, Hyperglycemia and ACE Inhibition 1727
were non-users of oral contraceptive medications, and
only during the follicular (low estrogen) phase of the
menstrual cycle. Finally, extrapolating from short-term
physiologic studies to a long-term condition which pro-
gresses over years can be tenuous. However, our aim was
to determine whether there are gender differences in the
renal physiologic profile in response to the major factors
that could conceivably promote or protect against pro-
gression of renal disease rather than to examine progres-
sion of disease over time, a project that would require a
much larger, long-term study.
CONCLUSION
We have demonstrated gender differences in baseline
renal hemodynamic function, the renal hemodynamic
response to short-term hyperglycemia and to ACE in-
hibitors, in subjects with uncomplicated type 1 diabetes
mellitus. These differences may be important in under-
standing the initiation and progression of diabetic re-
nal disease in men and women. Our study suggests that
women with type 1 diabetes mellitus respond more fa-
vorably to ACE inhibitors, with a beneficial reduction in
GFR and FF, but that hyperglycemia may impact more
negatively on their renal function, and may mitigate some
of the protective effects of female gender. Glycemic con-
trol, although crucial in the management of all patients
with type 1 diabetes mellitus, may be particularly impor-
tant in women.
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